Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

SUNITINIB SILVER 12,5 MG CÁPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/SUNITINIB SILVER 12,5 MG CÁPSULAS DURAS EFG

Approved

STANDARD

SUNITINIB SILVER 12,5 MG CÁPSULAS DURAS EFG

Silver Pharma S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Nov 21, 2022
Approval ID: c03f1946fed46673
Company: Silver Pharma S.L.
Type: Standard

Approval Details

Approval Id: c03f1946fed46673
Drug Cima Aemps Name: SUNITINIB SILVER 12,5 MG CÁPSULAS DURAS EFG
Register Number: 88306
Holder Company Name: Silver Pharma S.L.
Marketing Company Name: Silver Pharma S.L.
Authorization Date: 2022-11-21
Dosage Form: CÁPSULA DURA
Dose: 12.5 MG
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: Yes
Company Name: Silver Pharma S.L.

Active Ingredients

SUNITINIB MALATO

16,7 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Nov 21, 2022

Approval ID

c03f1946fed46673

Type

Standard

Back to CIMA-AEMPS Approvals